|Medtronic Named Among the World's Most Admired Companies by Fortune Magazine|
Ranked Second Within Medical Products and Equipment Category
DUBLIN - February 19, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, services and solutions, has been designated as one of the World's Most Admired Companies by FORTUNE Magazine. Within the Medical Products and Equipment industry category, Medtronic ranked second globally. This 2016 listing was released today, and is considered one of the leading measures of corporate reputation among the world's largest companies.
"It's an honor to be named by our business peers to Fortune magazine's list of most admired companies," said Omar Ishrak, chairman and CEO of Medtronic. "It's a tribute to the hard work of all 85,000 Medtronic employees and their dedication to our Mission of alleviating pain, restoring health and extending life for our patients."
Fortune magazine develops the Most Admired list by surveying top executives and board members from major corporations around the world, along with leading financial analysts. Companies are scored in nine key areas of financial performance and business management. The nine categories are: management quality; quality of products/services; innovation; value as a long-term investment; soundness of financial position; ability to attract, develop and retain talent; community responsibility; wise use of corporate assets; and effectiveness in conducting a global business. Click here for the full methodology.
This ranking is the latest by a third-party organization to recognize Medtronic for excellence. The company ranked fourth on Business Insider's list of Most Meaningful Companies to Work For in 2015, No. 31 on Business Insider's list of Best Companies to Work for in America and No. 14 on ComputerWorld's Best Places to Work in IT. In 2016 the Human Rights Campaign Foundation named Medtronic a Best Place to Work for LGBT Equality for the seventh consecutive year with a 100 percent Corporate Equality Index score.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.